前收市價 | 331.00 |
開市 | 330.40 |
買盤 | 310.00 x 無 |
賣出價 | 338.40 x 無 |
今日波幅 | 326.10 - 330.42 |
52 週波幅 | 306.80 - 350.50 |
成交量 | |
平均成交量 | 26,086,705 |
市值 | 30.009B |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 29.87 |
每股盈利 (最近 12 個月) | 0.11 |
業績公佈日 | 2024年8月01日 - 2024年8月15日 |
遠期股息及收益率 | 0.06 (1.77%) |
除息日 | 2024年3月14日 |
1 年預測目標價 | 364.20 |
Haleon plc (NYSE:HLN) Q1 2024 Earnings Call Transcript May 2, 2024 Haleon plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, welcome to the Haleon Q1 2024 Trading Update Conference Call. I am Davin, the chorus call […]
Consumer healthcare company Haleon reported first-quarter revenue slightly below market estimates on Wednesday, as volumes declined due to retailer destocking in U.S. and cooling demand for some of its medicines after a surge last year. The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth.
The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth. On a reported basis, revenue was down 2.2% on last year.